Performance analysis of Acumen Pharmaceuticals (ABOS)
Annual Return
Over the past 3 years, ABOS has had an average annual return of -33.02%, underperforming the benchmark SPY, which returned +19.63% annual.
Over the past 5 years, ABOS has had an average annual return of -33.51%, underperforming the benchmark SPY, which returned +12.73% annual.
Since Jul 1, 2021, ABOS has had an average annual return of -35.26%, underperforming the benchmark SPY, which returned +13.06% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| +5.62% | +22.66% | -55.18% | -28.92% | -20.10% | -66.37% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +23.24% | +20.71% | -24.84% | +1.28% | +8.83% | +2.63% | -16.49% | +5.62% | |||||
| 2025 | -12.85% | -14.61% | -14.13% | +2.74% | -9.79% | +13.81% | +20.80% | -2.87% | +25.70% | +29.26% | -15.00% | +12.30% | +22.66% |
| 2024 | -17.17% | +35.52% | -6.02% | -20.50% | -8.68% | -17.70% | +36.38% | -16.99% | -9.46% | +16.13% | -21.21% | -24.18% | -55.18% |
| 2023 | +21.66% | -19.79% | -22.96% | -4.95% | +27.76% | -2.45% | +53.87% | -18.66% | -31.05% | -54.96% | +28.39% | +59.97% | -28.92% |
| 2022 | -24.26% | +14.45% | -33.28% | -1.29% | -8.28% | +32.77% | +15.74% | +4.62% | +76.26% | -31.00% | -17.92% | -4.92% | -20.10% |
| 2021 | -22.99% | +15.76% | -17.07% | -5.45% | -43.78% | -14.43% | -66.37% |
Drawdown analysis of Acumen Pharmaceuticals (ABOS)
The maximum drawdown for the ABOS was -95.56%, occurring on Apr 17, 2025. This drawdown has not yet recovered.
The current ABOS drawdown is -89.01%.
Since Jul 1, 2021 ABOS has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.56% | Jul 2, 2021 | 952 | Apr 17, 2025 | Ongoing | Ongoing | Ongoing |